How Soon Can Ou Give Adenosine Again in Acls

What is Adenocard and how is it used?

Adenocard is a prescription medicine used to treat the symptoms of Paroxysmal Supraventricular Tachycardia (PSVT) and as a diagnostic for Stress Testing. Adenocard may be used alone or with other medications. Adenocard belongs to a class of drugs called Antidysrhythmics, V.

What are the possible side effects of Adenocard?

Adenocard may cause serious side effects including:

• abnormal heart rhythm (Torsades De Pointes),
• breast pain,
• premature atrial heartbeats,
• irregular heartbeat (likewise fast or too slow),
• trouble breathing,
• feeling pharynx tightness,
• heart attack,
• stroke,
• slowed middle rhythm,
• fast, irregular heartbeat,
• blurred vision,
• cough,
• complete stoppage of the heart,
• high claret pressure,
• lung failure,
• seizures, and
• wearisome heartbeat

Get medical aid right abroad, if you have whatever of the symptoms listed above.

The most common side effects of Adenocard include:

• facial flushing,
• shortness of breath,
• chest force per unit area,
• chest pain,
• nausea,
• headache,
• sweating,
• palpitations,
• low blood pressure level (hypotension),
• hyperventilation,
• head pressure level,
• lightheadedness,
• dizziness,
• tingling in arms,
• numbness,
• anticipation,
• blurred vision,
• burning awareness,
• heaviness in artillery,
• neck and back pain,
• metallic taste in mouth,
• tightness in throat, and
• pressure in groin

Tell the doctor if you take any side effect that bothers y'all or that does non go away.

These are not all the possible side effects of Adenocard. For more data, ask your doc or chemist.

Call your doctor for medical advice about side furnishings. You may report side furnishings to FDA at 1-800-FDA-1088.

FOR RAPID BOLUS INTRAVENOUS USE

Description

Adenosine is an endogenous nucleoside occurring in all cells of the torso. Information technology is chemically vi-amino-9-β-D-ribofuranosyl-9-H-purine and has the following structural formula:

Adenosine is a white crystalline powder. It is soluble in water and practically insoluble in alcohol. Solubility increases by warming and lowering the pH. Adenosine is not chemically related to other antiarrhythmic drugs. Adenocard® (adenosine injection) is a sterile, nonpyrogenic solution for rapid bolus intravenous injection. Each mL contains 3 mg adenosine and 9 mg sodium chloride in Water for Injection. The pH of the solution is between 4.5 and 7.5.

The Ansyr® plastic syringe is molded from a specially formulated polypropylene. H2o permeates from inside the container at an extremely slow rate which volition accept an insignificant effect on solution concentration over the expected shelf life.

Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the syringe material.

3 pharmacies about 11430 have coupons for adenocard (Make Names:Adenocard I.Five. for 2ML of 6MG/2ML)

INDICATIONS

Intravenous Adenocard (adenosine injection) is indicated for the following.

Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (east.g., Valsalva maneuver), should exist attempted prior to Adenocard administration.

It is of import to exist certain the Adenocard solution actually reaches the systemic circulation (encounter DOSAGE AND Assistants).

Adenocard does not convert atrial palpitate, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient pocket-sized slowing of ventricular response may occur immediately following Adenocard administration.

SLIDESHOW

Eye Disease: Symptoms, Signs, and Causes See Slideshow

DOSAGE AND Administration

For rapid bolus intravenous utilize only.

Adenocard (adenosine injection) should be given as a rapid bolus by the peripheral intravenous route. To be certain the solution reaches the systemic circulation, it should be administered either directly into a vein or, if given into an Four line, it should exist given as shut to the patient as possible and followed by a rapid saline flush.

Developed Patients

The dose recommendation is based on clinical studies with peripheral venous bolus dosing. Central venous (CVP or other) administration of Adenocard has not been systematically studied.

The recommended intravenous doses for adults are as follows:

Initial dose: 6 mg given equally a rapid intravenous bolus (administered over a i-ii 2nd menstruum).

Echo assistants: If the first dose does not outcome in elimination of the supraventricular tachycardia within ane-2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a 2d time if required.

Pediatric Patients

The dosages used in neonates, infants, children and adolescents were equivalent to those administered to adults on a weight ground.

Pediatric Patients with a Body Weight < 50 kg:

Initial dose: Give 0.05 to 0.1 mg/kg as a rapid Four bolus given either centrally or peripherally. A saline flush should follow.

Repeat administration: If conversion of PSVT does not occur within i-2 minutes, additional bolus injections of adenosine can exist administered at incrementally college doses, increasing the amount given by 0.05 to 0.one mg/kg. Follow each bolus with a saline flush. This procedure should continue until sinus rhythm is established or a maximum single dose of 0.3 mg/kg is used.

Pediatric Patients with a Body Weight ≥ fifty kg: Administer the adult dose.

Doses greater than 12 mg are not recommended for adult and pediatric patients.

Notation: Parenteral drug products should exist inspected visually for particulate affair and discoloration prior to administration.

HOW SUPPLIED

Adenocard® (adenosine injection) is supplied as a sterile not-pyrogenic solution in normal saline.

NDC 0469-8234-12 Product Code 823412
six mg/2 mL (iii mg/mL) in ii mL (fill book) Ansyr® plastic disposable syringe, in a packet of x.

NDC 0469-8234-14 Product Code 823414
12 mg/4 mL (three mg/mL) in 4 mL (fill book) Ansyr® plastic disposable syringe, in a package of x.

Shop at controlled room temperature 15º-30ºC (59º-86ºF).

DO Non Air-condition as crystallization may occur. If crystallization has occurred, deliquesce crystals past warming to room temperature. The solution must exist clear at the time of utilise.

Contains no preservatives. Discard unused portion.

May require needle or edgeless. To prevent needle-stick injuries, needles should not exist recapped, purposely bent or broken past hand.

REFERENCE

1. Paul T, Pfammatter. J-P. Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatric Cardiology 1997; eighteen:118-126

Marketed by: Astellas Pharma United states, Inc. Deerfield, IL 60015-2548. Manufactured by: Hospira, Inc. Lake Forest, IL 60045 USA.

SIDE Effects

The following reactions were reported with intravenous Adenocard (adenosine injection) used in controlled U.Due south. clinical trials. The placebo group had a less than one% rate of all of these reactions.

Cardiovascular

Facial flushing (xviii%), headache (2%), sweating, palpitations, chest pain, hypotension (less than one%).

Respiratory

Shortness of breath/dyspnea (12%), chest pressure (seven%), hyperventilation, head pressure (less than one%).

Cardinal Nervous Arrangement

Lightheadedness (2%), dizziness, tingling in artillery, numbness (1%), apprehension, blurred vision, called-for awareness, heaviness in arms, cervix and back pain (less than i%).

Gastrointestinal

Nausea (3%), metallic taste, tightness in throat, pressure in groin (less than i%).

Mail service Marketing Experience

(see WARNINGS)

The following adverse events have been reported from marketing experience with Adenocard. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably guess their frequency or found a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (ii) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.

Cardiovascular

Prolonged asystole, ventricular tachycardia, ventricular fibrillation, transient increase in blood force per unit area, bradycardia, atrial fibrillation, and Torsade de Pointes

Respiratory

Bronchospasm

Key Nervous System

Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness.

IMAGES

Come across Images

DRUG INTERACTIONS

Intravenous Adenocard (adenosine injection) has been effectively administered in the presence of other cardioactive drugs, such every bit quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without whatever change in the agin reaction profile. Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard (come across WARNINGS). Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents. The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation (see WARNINGS).

The effects of adenosine are antagonized past methylxanthines such as caffeine and theophylline. In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective. Adenosine furnishings are potentiated by dipyridamole. Thus, smaller doses of adenosine may exist effective in the presence of dipyridamole. Carbamazepine has been reported to increase the caste of heart block produced by other agents. Every bit the principal effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.

WARNINGS

Heart Cake

Adenocard (adenosine injection) exerts its effect by decreasing conduction through the A-5 node and may produce a short lasting commencement-, second- or third-caste centre cake. Appropriate therapy should be instituted every bit needed. Patients who develop loftier-level block on one dose of Adenocard should non be given additional doses. Because of the very brusk half-life of adenosine, these effects are mostly self-limiting. Advisable resuscitative measures should be available.

Transient or prolonged episodes of asystole accept been reported with fatal outcomes in some cases. Rarely, ventricular fibrillation has been reported following Adenocard administration, including both resuscitated and fatal events. In near instances, these cases were associated with the concomitant utilize of digoxin and, less frequently with digoxin and verapamil. Although no causal human relationship or drug-drug interaction has been established, Adenocard should be used with caution in patients receiving digoxin or digoxin and verapamil in combination.

Arrhythmias at Time of Conversion

At the time of conversion to normal sinus rhythm, a diversity of new rhythms may announced on the electrocardiogram. They generally final only a few seconds without intervention, and may take the form of premature ventricular contractions, atrial premature contractions, atrial fibrillation, sinus bradycardia, sinus tachycardia, skipped beats, and varying degrees of A-V nodal cake. Such findings were seen in 55% of patients.

Bronchoconstriction

Adenocard (adenosine injection) is a respiratory stimulant (probably through activation of carotid torso chemoreceptors) and intravenous administration in man has been shown to increment minute ventilation (Ve) and reduce arterial PCO₂ causing respiratory alkalosis.

Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These furnishings have not been observed in normal subjects. Adenocard has been administered to a limited number of patients with asthma and balmy to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenocard should exist used with caution in patients with obstructive lung illness not associated with bronchoconstriction (due east.g., emphysema, bronchitis, etc.) and should exist avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenocard should be discontinued in any patient who develops severe respiratory difficulties.

QUESTION

In the U.Due south., i in every 4 deaths is caused by heart affliction. Run across Answer

PRECAUTIONS

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies in animals have not been performed to evaluate the carcinogenic potential of Adenocard (adenosine injection). Adenosine was negative for genotoxic potential in the Salmonella (Ames Test) and Mammalian Microsome Assay.

Adenosine, however, similar other nucleosides at millimolar concentrations present for several doubling times of cells in culture, is known to produce a variety of chromosomal alterations. Fertility studies in animals have non been conducted with adenosine.

Pregnancy Category C

Fauna reproduction studies have not been conducted with adenosine; nor accept studies been performed in pregnant women. As adenosine is a naturally occurring textile, widely dispersed throughout the torso, no fetal effects would be anticipated. Withal, since information technology is not known whether Adenocard tin cause fetal harm when administered to pregnant women, Adenocard should be used during pregnancy simply if clearly needed.

Pediatric Use

No controlled studies accept been conducted in pediatric patients to establish the condom and efficacy of Adenocard for the conversion of paroxysmal supraventricular tachycardia (PSVT). Nevertheless, intravenous adenosine has been used for the treatment of PSVT in neonates, infants, children and adolescents (see DOSAGE AND ADMINISTRATION).

Geriatric Use

Clinical studies of Adenocard did non include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has non identified differences in responses between elderly and younger patients. In full general, Adenocard in geriatric patients should be used with caution since this population may take a diminished cardiac office, nodal dysfunction, concomitant diseases or drug therapy that may alter hemodynamic office and produce astringent bradycardia or AV block.

Overdosage & Contraindications

OVERDOSE

The half-life of Adenocard (adenosine injection) is less than 10 seconds. Thus, adverse furnishings are generally rapidly self-limiting. Treatment of any prolonged agin effects should be individualized and be directed toward the specific effect. Methylxanthines, such as caffeine and theophylline, are competitive antagonists of adenosine.

CONTRAINDICATIONS

Intravenous Adenocard (adenosine injection) is contraindicated in:

1. 2nd- or tertiary-degree A-V block (except in patients with a functioning artificial pacemaker).
2. Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a performance artificial pacemaker).
3. Known hypersensitivity to adenosine.

SLIDESHOW

Center Disease: Symptoms, Signs, and Causes Come across Slideshow

CLINICAL PHARMACOLOGY

Mechanism of Action

Adenocard (adenosine injection) slows conduction time through the A-V node, can interrupt the reentry pathways through the A-Five node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.

Adenocard is antagonized competitively past methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such equally dipyridamole. Adenocard is not blocked by atropine.

Hemodynamics

The intravenous bolus dose of 6 or 12 mg Adenocard (adenosine injection) usually has no systemic hemodynamic effects. When larger doses are given by infusion, adenosine decreases blood pressure past decreasing peripheral resistance.

Pharmacokinetics

Intravenously administered adenosine is speedily cleared from the circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells. This process involves a specific transmembrane nucleoside carrier system that is reversible, nonconcentrative, and bidirectionally symmetrical. Intracellular adenosine is chop-chop metabolized either via phosphorylation to adenosine monophosphate past adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Since adenosine kinase has a lower K_m and Five_max than adenosine deaminase, deamination plays a meaning role but when cytosolic adenosine saturates the phosphorylation pathway. Inosine formed by deamination of adenosine can get out the jail cell intact or tin be degraded to hypoxanthine, xanthine, and ultimately uric acrid. Adenosine monophosphate formed by phosphorylation of adenosine is incorporated into the high-energy phosphate pool. While extracellular adenosine is primarily cleared by cellular uptake with a one-half-life of less than 10 seconds in whole claret, excessive amounts may be deaminated by an ecto-course of adenosine deaminase. As Adenocard requires no hepatic or renal function for its activation or inactivation, hepatic and renal failure would non exist expected to alter its effectiveness or tolerability.

Clinical Trial Results

In controlled studies in the United States, bolus doses of iii, vi, 9, and 12 mg were studied. A cumulative 60% of patients with paroxysmal supraventricular tachycardia had converted to normal sinus rhythm inside ane minute after an intravenous bolus dose of six mg Adenocard (some converted on 3 mg and failures were given six mg), and a cumulative 92% converted after a bolus dose of 12 mg. Seven to sixteen percent of patients converted after one-iv placebo bolus injections. Like responses were seen in a variety of patient subsets, including those using or not using digoxin, those with Wolff-Parkinson-White Syndrome, males, females, blacks, Caucasians, and Hispanics.

Adenosine is non effective in converting rhythms other than PSVT, such as atrial flutter, atrial fibrillation, or ventricular tachycardia, to normal sinus rhythm.

PATIENT Information

No information provided. Delight refer to the WARNINGS and PRECAUTIONS sections.

From

Study Problems to the Food and Drug Assistants

You are encouraged to study negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or phone call one-800-FDA-1088.

coxweref1941.blogspot.com

Source: https://www.rxlist.com/adenocard-drug.htm

Share this post